Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iSpecimen (ISPC) Income from Continuing Operations: 2020-2025

Historic Income from Continuing Operations for iSpecimen (ISPC) over the last 6 years, with Sep 2025 value amounting to -$2.8 million.

  • iSpecimen's Income from Continuing Operations fell 65.34% to -$2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.3 million, marking a year-over-year decrease of 26.75%. This contributed to the annual value of -$12.9 million for FY2024, which is 18.55% down from last year.
  • Per iSpecimen's latest filing, its Income from Continuing Operations stood at -$2.8 million for Q3 2025, which was down 55.40% from -$1.8 million recorded in Q2 2025.
  • Over the past 5 years, iSpecimen's Income from Continuing Operations peaked at -$1.6 million during Q3 2021, and registered a low of -$6.0 million during Q4 2024.
  • Its 3-year average for Income from Continuing Operations is -$2.7 million, with a median of -$2.4 million in 2023.
  • As far as peak fluctuations go, iSpecimen's Income from Continuing Operations crashed by 141.97% in 2021, and later spiked by 44.95% in 2025.
  • iSpecimen's Income from Continuing Operations (Quarterly) stood at -$2.0 million in 2021, then fell by 6.51% to -$2.2 million in 2022, then plummeted by 30.96% to -$2.8 million in 2023, then slumped by 111.96% to -$6.0 million in 2024, then crashed by 65.34% to -$2.8 million in 2025.
  • Its Income from Continuing Operations was -$2.8 million in Q3 2025, compared to -$1.8 million in Q2 2025 and -$1.6 million in Q1 2025.